Replies to post #227873 on Biotech Values

[zipjet]

>>Wouldn’t the limited availability of Vascepa API substantially impede competition, at least in the short run?

Sure.

But then when we do a valuation, the DCF plummets as COGS% rises steeply over time.

$AMRN is not cheap at $7.5B. What is it worth without patent protection?

>>...wouldn’t it take an extended time for a free-for-all market to ensue?

Yes, it will take some time. Not sure how long. How many competitors does it take to approach pure competition when the only differentiator is price?